ClinicalTrials.gg
CompletedNCT05161741RISEUpdated Feb 6, 2023

Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of Insulin in Adverse Drug Event, Effect of Drug and Type 2 Diabetes Treated With Insulin, sponsored by Getz Pharma. Completed at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-06.

Sponsored by Getz Pharma · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jan 2021, registered Dec 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
238
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Objective: To evaluate the safety and efficacy of Human Insulin rDNA (Insuget) in patients with Type II Diabetes Mellitus.

Study Design: Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.

Sample size: The estimated target sample size is n=230. Study duration: 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date)

After recruitment, patient is supposed to have three visits for follow-ups. Visit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.

  • Primary (SAFETY Outcomes):

    • Frequency of adverse events during the course of study follow-up.
    • Frequency of serious adverse events.
  • SECONDARY OUTCOME MEASURES (EFFICACY ENDPOINTS)

    • Change from baseline in HbA1c% to the last-observation.
    • Change from baseline in fasting plasma glucose to the last- observation on treatment

Ethical consideration:

The ethical approval of study is taken from an independent ethics committee. The study will be conducted in compliance with the protocol, good clinical practices (GCP), the ethical principles that have their origin in the Declaration of Helsinki and the applicable regulatory requirements.

Read the detailed description

OBJECTIVE To evaluate the safety and efficacy of Human Insulin rDNA (Insuget) in patients with Type II Diabetes Mellitus.

METHODOLOGY:

STUDY DESIGN:

Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.

SAMPLE SIZE As per cited literature, the reported hypoglycemia rate was 41% in patients who underwent treatment of Human Regular Insulin.

Considering 10% increase of hypoglycemia incidence in current study from the reference literature and keeping 95% confidence level, 5% margin of error and 80% power of study, the calculated sample size is n=191. After adding 20% attrition rate, the target enrollment would be n=230.

NUMBER OF SITES Total 04-05 sites.

STUDY DURATION 10-12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date)

SAMPLING TECHNIQUE A non-probability consecutive sampling method will be used to screen patients as per study eligibility criteria.

LABORATORY TESTING:

Reputable laboratory is considered for testing of diabetes patients i.e. HbA1c and FBG. The certified clinical lab will be responsible for receiving and analyzing clinical sample.

HbA1c and FBG readings would be recorded within ±10 days of the follow up visit and FBG ±03 day of the follow up visit or average of last three reading in the diary reported by patient, respectively.

SCREENING / BASELINE VISIT After taking the informed consent, the patient will be screened as per the defined criteria and further will be initiated on Insuget (Human Insulin rDNA).

The following data will be recorded on the baseline visit.

  • Date of visit
  • Inclusion \& Exclusion criteria will be evaluated for enrollment
  • Demographic data: Age (years), Gender
  • Physical parameters i-e weight (kg), height (inches), BMI (Kg/m2)
  • Duration of Diabetes (years)
  • Smoking status: Yes / No
  • Education Level: Graduate or above / Secondary or below / No Formal Education
  • Blood pressure readings (mm/Hg)
  • Concomitant Disease and Therapy Details

Laboratory Investigations:

  • HbA1c and FBS

    • Insulin use status
  • Insulin naïve or already on insulin therapy with dose/frequency details

VISIT 1 (1st follow-up visit; after 4 to 6 weeks of initiation of therapy)

Each patient will have a unique study patient number; the following information will be recorded at the 1st follow-up visit:

  • Date of visit
  • Physical parameters i-e weight (kg)
  • Blood pressure

Laboratory Investigations:

o FBS

Safety Evaluation i-e Hypoglycemia; Symptoms of Hypoglycemia: Headache, Feeling of Hunger, Drowsiness, Blurred Vision, Sweating, Nausea, Confusion, Dizziness, Tachycardia, Tremor and others.

  • Hypokalemia; Muscle Cramps, Weakness, Irregular Heart Beat and others
  • Injection Site Related Adverse Events; Pain, Redness, Irritation, Lipodystrophy and others.

Review of Patient Diary and reporting Self-monitoring blood glucose: Last three readings average will be taken for fasting blood glucose.

Reports of any serious adverse events leading to hospitalization i-e severe hypoglycemia.

VISIT 2 (2nd follow-up visit; after 3 months of initiation of therapy)

Each patient will have a unique study patient number; the following information will be recorded at the 1st follow-up visit:

  • Date of visit
  • Physical parameters i-e weight (kg)
  • Blood pressure

Laboratory Investigations:

-HbA1c and FBS

Safety Evaluation i-e

  • Hypoglycemia; Symptoms of Hypoglycemia: Headache, Feeling of Hunger, Drowsiness, Blurred Vision, Sweating, Nausea, Confusion, Dizziness, Tachycardia, Tremor and others.
  • Hypokalemia; Muscle Cramps, Weakness, Irregular Heart Beat and others.
  • Injection Site Related Adverse Events; Pain, Redness, Irritation, Lipodystrophy and others.

Review of Patient Diary and reporting Self-monitoring blood glucose: Last three readings average will be taken for fasting blood glucose.

Reports of any serious adverse events leading to hospitalization i-e severe hypoglycemia.

VISIT 3 (3rd follow-up visit at 6 months of initiation of therapy)

Each patient will have a unique study patient number; the following information will be recorded at the 1st follow-up visit:

  • Date of visit
  • Physical parameters i-e weight (kg)
  • Blood pressure

Laboratory Investigations:

-HbA1c and FBS

Safety Evaluation i-e

  • Hypoglycemia; Symptoms of Hypoglycemia: Headache, Feeling of Hunger, Drowsiness, Blurred Vision, Sweating, Nausea, Confusion, Dizziness, Tachycardia, Tremor and others.
  • Hypokalemia; Muscle Cramps, Weakness, Irregular Heart Beat and others.
  • Injection Site Related Adverse Events; Pain, Redness, Irritation, Lipodystrophy and others.

Review of Patient Diary and reporting

  • Self-monitoring blood glucose: Last three readings average will be taken for fasting blood glucose.
  • Reports of any serious adverse events leading to hospitalization i-e severe hypoglycemia.

STUDY TREATMENT After obtaining consent and baseline assessment, the patient will be advised to start Insuget (Human Insulin rDNA) and will be assessed in follow-up visits as per the defined parameters.

DOSE \& FREQUENCY OF STUDY TREATMENT The investigator will recommend the dose of Insuget 70/30 (Local Insulin brand) and/or Insuget N (Local Insulin brand) and/or Insuget R (Local Insulin brand) as per standard clinical practices to meet the daily requirements of study patients.

The drug frequency will be at the discretion of the treating physician. Patients included in the study will be administered treatment according to the standard guidelines.

CONCOMITANT TREATMENT Concomitant treatment for hypertension, dyslipidemia, and other associated diseases will be continued as per the physician's discretion and/or according to the standard guidelines. Similarly, other treatments can be initiated during the course of the study as and when needed. All concomitant medications must be documented.

DATA COLLECTION An electronic data capture system will be used for this study. An electronic database will be designed to record the data required by the protocol and collected by the investigator. All personal data will be coded with a unique number; the researcher will securely keep codes at the research site. Potential participant will have to sign the consent to take part in the study but all personal data collected during the study will be dealt with strict confidentiality and will be used for the research in coded form.

Coded data will be transferred and processed following applicable laws, regulations protecting processing, and transfer of coded data. As per data protection laws and regulations, patients may be titled to access, rectify and ask for the deletion of their personal data via their doctors who are the only person to know the correspondence between the participant number and identity. Personal data will be kept until the publication of the results of the study and will then be archived.

DISCONTINUATION OF TREATMENT Any significant adverse event, which leads to discontinuation from the study treatment. The time and reason for discontinuation will be recorded in the CRF.

DATA MANAGEMENT AND STATISTICAL ANALYSIS Statistical analyses will be performed using SPSS version-22. Mean ±standard deviation will be calculated for continuous variables like age, height, weight, BMI, blood pressure, duration of diabetes, HbA1c and FBS whereas categorical variables will be presented as frequencies and percentages (gender, smoking status, education level, comorbidities, adverse events, etc). Age will be stratified to evaluate the association of reported adverse events with age group and other categorical variable will be assessed through chi-square test. ANOVA will be applied to determine the reduction of HbA1c, FBS, Weight, BMI and Blood Pressure from baseline to 6 months follow-up. A normality test will be done for consideration of parametric or non-parametric application of significance tests. P-value \<0.05 will be considered statistically significant.

02

Conditions studied

  • Adverse Drug Event
  • Effect of Drug
  • Type 2 Diabetes Treated With Insulin

Keywords

  • Insulin
  • Type 2 Diabetes mellitus
  • Safety
  • Efficacy
03

In context

Drug-Related Side Effects and Adverse Reactions

449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.

This study's enrollment of 238 is above the median of 108 across 262 interventional studies indexed under Drug-Related Side Effects and Adverse Reactions.

Browse Drug-Related Side Effects and Adverse Reactions studies →

Lead sponsor

Getz Pharma is the lead sponsor of 19 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who give written .
  • Type 2 diabetic males \& females with age 18 \& above years.
  • : 7.0% and above.
  • Patients with uncontrolled Diabetes after intervention of lifestyle modifications plus oral and/or insulin therapy.

Exclusion criteria

Exclusion Criteria:

  • Known type 1 diabetes mellitus patients.
  • History of severe hypoglycemia (\<70mg/dL)
  • History of to any of the active or inactive ingredients of the insulin preparations used in the trial, and/or history of significant allergic drug reactions.
  • Presence of severe diabetes complications.
  • History of renal and/or hepatic dysfunctions.
  • Patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state.
  • History of acute coronary syndrome or stroke.
  • Pregnant or lactating females.
  • History of Acute psychiatric disorder or exacerbation of chronic psychiatric disorder.
  • History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
238 participants (actual)

Study arms

  • Experimental
    Uncontrolled diabetes requiring Insulin

    Drug: Insulin

Interventions

  • Human rDNA Insulin (Insuget, local brand of Getz Pharma)

06

What researchers measure

Primary outcomes

  1. Frequency of adverse events, serious adverse events during the course of study follow-up

    Drug safety

    Time frame: 6 months

  2. Change from baseline in HbA1c% to the last-observation

    Drug efficacy

    Time frame: 6 months

  3. Change from baseline in fasting plasma glucose to the last- observation on treatment

    Drug efficacy

    Time frame: 6 months

07

Study locations

1 site
  • Social Security Hospital
    Lahore, Punjab 54500, Pakistan
08

References and documents

Publications

  • American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008 Jan;31 Suppl 1:S55-60. doi: 10.2337/dc08-S055. No abstract available. PubMed 18165338 ↗
  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum In: Lancet 1999 Aug 14;354(9178):602. PubMed 9742976 ↗
  • Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999 Jun 2;281(21):2005-12. doi: 10.1001/jama.281.21.2005. PubMed 10359389 ↗
  • Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002 Feb;25(2):330-6. doi: 10.2337/diacare.25.2.330. Erratum In: Diabetes Care 2002 Jul;25(7):1268. PubMed 11815505 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Nov 2022, 22 months.

Of 18 phase 4 interventional studies under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 37. This study's 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2021
First posted
Dec 17, 2021
StartActual
Jan 1, 2021
Primary completionActual
Nov 30, 2022
CompletionActual
Nov 30, 2022
Last update
Feb 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05161741
Lead sponsor
Getz Pharma
Responsible party
Sponsor
First posted
Dec 17, 2021
Start date
Jan 1, 2021
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Last update
Feb 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion